Compare · AZN vs ROIV
AZN vs ROIV
Side-by-side comparison of AstraZeneca PLC (AZN) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 10.0x ROIV ($26.34B).
- Over the past year, AZN is down 9.9% and ROIV is up 208.5% - ROIV leads by 218.3 points.
- AZN has been more active in the news (13 items in the past 4 weeks vs 10 for ROIV).
- AZN has more recent analyst coverage (25 ratings vs 18 for ROIV).
- Company
- AstraZeneca PLC
- Roivant Sciences Ltd.
- Price
- -
- -
- Market cap
- $263.10B
- $26.34B
- 1M return
- -0.09%
- +5.19%
- 1Y return
- -9.89%
- +208.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 13
- 10
- Recent ratings
- 25
- 18
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest ROIV
- CFO Pulik Richard covered exercise/tax liability with 5,749 shares, decreasing direct ownership by 2% to 271,810 units (SEC Form 4) (withholding obligation)
- President & Immunovant CEO Venker Eric covered exercise/tax liability with 13,909 shares, decreasing direct ownership by 0.86% to 1,599,154 units (SEC Form 4) to cover withholding tax
- President & CIO Sukhatme Mayukh sold $12,360,813 worth of shares (335,174 units at $36.88) and exercised 335,174 shares at a strike of $3.85 (SEC Form 4)
- President & CIO Sukhatme Mayukh exercised 664,826 shares at a strike of $3.85 and sold $24,160,402 worth of shares (664,826 units at $36.34) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.
- SEC Form 10-Q filed by Roivant Sciences Ltd.
- Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
- Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)